GR1803 injection

DRUG5 trials

Sponsors

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Conditions

Auto Immune DiseaseMultiple MyelomaMultiple Myeloma (MM)Systemic Lupus Erthematosus

Phase 1

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not yet recruitingNCT07090954

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Multiple Myeloma

Start: 2025-08-31End: 2030-01-31Target: 32Updated: 2025-07-29

Phase I Trial of GR1803 Injection in Patients With RRMM

CompletedNCT07102706

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Multiple Myeloma (MM)

Start: 2022-05-27End: 2025-05-20Updated: 2025-08-05

A Study of GR1803 in Systemic Lupus Erythematosus

RecruitingNCT07348055

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Auto Immune Disease, Systemic Lupus Erthematosus

Start: 2026-02-02End: 2027-12-01Target: 44Updated: 2026-03-10

Phase 2

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Active, not recruitingNCT06566547

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Multiple Myeloma

Start: 2024-08-26End: 2027-08-01Target: 116Updated: 2026-05-27

Phase 3

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingNCT07452198

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Multiple Myeloma

Start: 2026-03-09End: 2030-03-01Target: 358Updated: 2026-03-25